Iridex Receives CE Mark for Transilluminated Probe
March 20 2018 - 8:00AM
IRIDEX Corporation (Nasdaq:IRIX) is pleased to announce the
availability of the G-Probe Illuminate™ device in Europe. The
probe, now with CE mark, offers combined transillumination and
laser fiber for targeted transscleral cyclophotocoagulation (CPC).
The G-Probe Illuminate received FDA clearance and was launched in
early 2017. It is the third member of the family of probes powered
by the CYCLO G6™ Glaucoma Laser System. This delivery device
features built-in transillumination, which optimizes placement of
the probe and therapeutic outcomes.
Studies have shown the ciliary body, the target tissue for a CPC
treatment, naturally varies in location between patients, and cases
of abnormal ocular size, high myopia and post-corneal transplants
generate even more challenges. The G-Probe Illuminate may improve
the ability of physicians to locate the ciliary body and deliver
the laser treatment in a more targeted manner.
“The G-Probe Illuminate is a highly-anticipated product for me.
This new design will help me deliver a targeted
cyclophotocoagulation treatment with increased visualization of the
ciliary body and surrounding working areas”, says Marc
Töteberg-Harms, MD, FEBO. “G-Probe Illuminate allows me to treat my
patients with precise accuracy to the desired tissue, especially in
patients with abnormal anatomy.”
The G-Probe Illuminate may be utilized in the operating room or
as an outpatient, office-based procedure providing a versatile
option for treating glaucoma. “The prevalence of glaucoma is only
increasing around the world, and IRIDEX is committed to improving
and expanding the therapeutic options for both patients and
surgeons,” says IRIDEX CEO, William M. Moore.
About IRIDEX
IRIDEX Corporation is a worldwide leader in developing,
manufacturing, and marketing innovative and versatile laser-based
medical systems, delivery devices and consumable instrumentation
for the ophthalmology market. The Company’s proprietary MicroPulse®
technology delivers a differentiated treatment that provides safe,
effective, and proven treatment for targeted sight-threatening eye
conditions. IRIDEX’s current product line is used for the treatment
of glaucoma, diabetic macular edema (DME) and other retinal
diseases. IRIDEX products are sold in the United States through a
direct sales force and internationally primarily through a network
of independent distributors into more than 100 countries. For
further information, visit the IRIDEX website at
http://www.iridex.com/.
Safe Harbor Statement
This announcement contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Act of 1934, as amended,
including those statements concerning the adoption and effect of
Company products on its results, the markets in which the Company
operates, the Company’s future financial results, and the Company's
strategic plans and objectives. These statements are not guarantees
of future performance and actual results may differ materially from
those described in these forward-looking statements as a result of
a number of factors. Please see a detailed description of these and
other risks contained in our Annual Report on Form 10-K for the
fiscal year ended December 30, 2017, and Quarterly Reports on Form
10-Q for subsequent fiscal quarters, each of which was filed with
the Securities and Exchange Commission. Forward-looking statements
contained in this announcement are made as of this date and will
not be updated.
Media Contact:Jamie Hall Pascale
Communications,
LLC.724-417-0167jamie@pascalecommunications.com
Investor Relations Contact:Lynn Pieper Lewis or
Leigh Salvo(415) 937-5404investors@iridex.com
IRIDEX (NASDAQ:IRIX)
Historical Stock Chart
From Mar 2024 to Apr 2024
IRIDEX (NASDAQ:IRIX)
Historical Stock Chart
From Apr 2023 to Apr 2024